Cell Analysis Global Market - Forecast to 2029

Publishing Date : August, 2022
Report Code : HCBT0103
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

 

Cells constitute discrete units of biological function and serve as starting points in a myriad of studies to identify and map many of the basic biochemical and physical processes of life. Cell analysis is important to understand, predict, and ultimately analyze factors that underlie cell health, proliferation, function, and death by using various technologies such as PCR, Sequencing, Microfluidics, Spectrometry, Microscopes, High content analysis and others. All these technologies play a major role in gene, protein and RNA expression analysis of cells, having application in research, diagnosis and therapeutics development. Continuous advancements in technologies significantly revealed the heterogeneity, which will further enhance the cell analysis application.

According to IQ4I analysis, the cell analysis global market is expected to grow at a low single digit CAGR from 2022 to 2029 to reach $38,020.6 million by 2029. The rising incidence of infectious and non-infectious diseases and demand for early detection, diagnosis & treatment, increasing government and private funding towards cell based research, increasing advancements in cell imaging technologies to reduce the cost & time during the drug discovery process are driving the cell analysis market. Growing focus on personalized medicine and the introduction of advanced technologies in cell analysis provides immense opportunities to the cell analysis market. However, stringent government regulations, availability of alternative technologies, lack of skilled personnel to use advanced cell analysis Instruments, and the high cost of some of the instruments are expected to hamper the market growth.

The market for cell analysis is segmented based on technique, product, application, end-user and geography. The cell analysis techniques global market is segmented into PCR, Sequencing, Microfluidics and Microarrays, Spectrometry, Microscopy, Cytometry, High Content Analysis, Electrophoresis and Others. Among the techniques, the PCR segment accounted for the largest revenue in 2022. The Sequencing segment is expected to grow at a double digit CAGR from 2022 to 2029.

The cell analysis products market is mainly segmented into consumables, instruments, software and services. Among these, consumables segment commanded the largest revenue in 2022 and is expected to grow at a low single digit CAGR from 2022 to 2029. The software and services segment is expected to grow at a mid single digit CAGR from 2022 to 2029.

The consumables market is further sub-segmented into reagents, assay kits, microplates and others. Among the consumables sub-segments, the assay kits held the largest revenue in 2022. Reagents sub-segment is the fastest growing segment with a mid single digit CAGR from 2022 to 2029.

The instrument segment is further classified into cell counters, cell microarray and microfluidics, liquid handling systems, cytometers, microfluidic devices, high content screening (HCS) systems, microplate readers, PCR devices, sequencing instruments, spectrometer, microscopes and others. Among the instruments, the PCR instruments is commanded the largest revenue of in 2022 and is expected to grow at a CAGR of xx% from 2022 to 2029 to reach $xx million by 2029. Cell Microarrays and Microfluidics are expected to grow at a low single digit CAGR of from 2022 to 2029 due to increasing advancements in microfluidic technologies mainly for single-cell analysis applications.

The application market is categorized based on processes, field, and by therapeutic area. In the process of application, the market is segmented into cellular processes, signal transduction pathways, circulating tumor cells, single-cell analysis, epigenetic target analysis, subpopulation characterization, and drug and candidate screening. Cellular process application accounted for the largest revenue in 2022 and is expected to grow at a CAGR of xx% from 2022 to 2029. The single-cell analysis market is expected to boom at a high single digit CAGR from 2022 to 2029 due to increasing advancement in single-cell technologies. Based on field of application, the market is further segmented into forensic, therapeutics, cell imaging, biomarker research, genomic analysis, stem cell analysis, and diagnostics. Diagnostics held the largest revenue of in 2022. Stem cell analysis is the fastest-growing segment at a mid single digit from 2022 to 2029. The cell imaging market is further segmented into live-cell imaging which commanded revenue of $xx million in 2022 and is expected to grow at a mid single digit CAGR from 2022 to 2029. Based on therapeutic area, the market is further segmented into cancer, infectious disease, genetic testing, immunology, and others. The Infectious diseases accounted for the largest revenue in 2022. Cancer is the fastest-growing segment with a mid single digit CAGR from 2022 to 2029.

The end-users market is segmented into hospitals & diagnostic laboratories, academic and research institutes, contract research organizations (CROs), pharmaceuticals and biotechnology companies, cell banks, and others. Hospitals & Diagnostic laboratories generated the largest revenue in 2022. Academic and research laboratories are expected to grow at a mid single digit CAGR from 2022 to 2029.

Based on geography, the cell analysis global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, U.K. and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of APAC) and Rest of the world (Brazil, Rest of Latin America and the Middle East & Africa). North America accounted for the largest revenue in 2022 and is expected to reach $xx million by 2029 growing at a low single digit CAGR from 2022 to 2029. The factors such as increasing R&D expenditure, increasing incidence of infectious and non-infectious disease, increasing government funding towards the therapeutic and diagnostic research, presence of major players, increasing scope for the cell analysis application in drug discovery, increasing interest towards personalized medicine and development of the innovative platform for high growth potential single-cell analysis application are driving the market.

The Asia-Pacific is the fastest-growing region in the cell analysis global market with a revenue of $xx million in 2022 and is expected to reach $xx million by 2029 growing at a low single digit CAGR from 2022 to 2029 which is attributed to the increased scope for research activities in academic & research institutes, increasing outsourcing, increased incidence of chronic diseases (cancer) and infectious disease, increasing awareness about early screening (cancer) and prenatal test and their adoption in clinical care, increasing government and private investment for - cell-based research and also for the development & expansion single-cell analysis technologies and increasing number startup companies engaged in the development innovative solutions. However, lack of technical expertise, high cost of instruments, lack of skilled labors, and large scale clinical data challenges are some of the restraints for the cell analysis market in the region.

The cell analysis global market is competitive and all the players in this market are involved in innovating new and advanced products to maintain their market shares. The key players in the cell analysis global market include Agilent Technologies, Inc. (U.S.), Becton Dickinson and Company (U.S.), Illumina Inc. (U.S.), Bio-Rad Laboratories (U.S.), Danaher Corporation (U.S.), Merck KGaA (Germany), PerkinElmer, Inc. (U.S.), Qiagen N.V. (Netherlands), Thermo Fisher Scientific, Inc. (U.S.), Roche Holdings, Inc. (Switzerland), Abbott Laboratories (U.S.) and 10X Genomics (U.S.)

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • U.S.
  • Rest of North America
  • Europe
  • Germany
  • U.K.
  • France
  • Rest of Europe
  • Asia-Pacific 
  • Japan
  • China
  • India
  • Rest of APAC
  • Rest of the World (Row)
  • Brazil
  • Rest of LATAM
  • The Middle East and Africa   

 

    TABLE OF CONTENTS

    • 1     EXECUTIVE SUMMARY
    • 2     INTRODUCTION
      • 2.1     KEY TAKEAWAYS
      • 2.2     SCOPE OF THE REPORT
      • 2.3     REPORT DESCRIPTION
      • 2.4     MARKETS COVERED
      • 2.5     STAKEHOLDERS
      • 2.6     RESEARCH METHODOLOGY
        • 2.6.1     MARKET SIZE ESTIMATION
        • 2.6.2     MARKET BREAKDOWN & DATA TRIANGULATION
        • 2.6.3     SECONDARY SOURCES
        • 2.6.4     KEY DATA POINTS FROM SECONDARY SOURCES
        • 2.6.5     PRIMARY SOURCES
        • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
        • 2.6.7     ASSUMPTIONS
    • 3     MARKET ANALYSIS
      • 3.1     INTRODUCTION
      • 3.2     MARKET SEGMENTATION
      • 3.3     FACTORS INFLUENCING MARKET
        • 3.3.1     DRIVERS AND OPPORTUNITIES
          • 3.3.1.1     Rising incidence of infectious and non-infectious diseases and demand for early detection, diagnosis & treatment
          • 3.3.1.2     Increasing government and private funding
          • 3.3.1.3     Increasing advancements in cell imaging technologies reduce the cost and time consumption for the drug discovery process
          • 3.3.1.4     Growing focus on personalized medicine
          • 3.3.1.5     Introduction of advanced technologies in cell analysis
          • 3.3.1.6     Increasing merger and acquisition activities in cell analysis
        • 3.3.2     RESTRAINTS & THREATS
          • 3.3.2.1     Lack of skilled personnel to use advanced cell analysis instruments
          • 3.3.2.2     Expensive cell analysis instruments
          • 3.3.2.3     Maintaining consistency, reproducibility of assays and lack of standardization
          • 3.3.2.4     Avalbility of alternative technlogies
          • 3.3.2.5     Stringent regulatory framework limits advancements in cellular analysis market
      • 3.4     REGULATORY AFFAIRS
        • 3.4.1     U.S.
        • 3.4.2     EUROPE
        • 3.4.3     CHINA
        • 3.4.4     INDIA
        • 3.4.5     JAPAN
      • 3.5     FUNDING SCENARIO
      • 3.6     CELL ANALYSIS – DEALS, AND NEW PRODUCT LAUNCH
      • 3.7     TECHNOLOGICAL ADVANCEMENTS
        • 3.7.1     INTRODUCTION
        • 3.7.2     CRISPER LIVE CELL IMAGING
        • 3.7.3     SINGLE-CELL MULTI-OMICS
        • 3.7.4     RAMAN LIVE CELL IMAGING
        • 3.7.5     DROPLET-BASED MICROFLUIDICS IN SINGLE-CELL ANALYSIS
        • 3.7.6     INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY IN SINGLE-CELL ANALYSIS (ICP-MS)
        • 3.7.7     DEEP LEARNING AND AI IN MICROSCOPY
        • 3.7.8     INTELLIGENT IMAGE-ACTIVATED CELL SORTING OR AI-DRIVEN CELL ISOLATION TECHNOLOGY
        • 3.7.9     ADVANCED SPATIAL TECHNOLOGIES IN CELL ANALYSIS
        • 3.7.10     DIGITAL MICROFLUIDIC ISOLATION OF SINGLE-CELLS FOR -OMICS (DISCO)
      • 3.8     IMPACT OF COVID-19 ON CELL ANALYSIS MARKET
      • 3.9     PORTER’S FIVE FORCE ANALYSIS
        • 3.9.1     THREAT OF NEW ENTRANTS
        • 3.9.2     THREAT OF SUBSTITUTES
        • 3.9.3     COMPETITIVE RIVALRY
        • 3.9.4     BARGAINING POWER OF SUPPLIERS
        • 3.9.5     BARGAINING POWER OF BUYERS
      • 3.1     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
        • 3.10.1     CELL ANALYSIS GLOBAL MARKET SHARE ANALYSIS
        • 3.10.2     MARKET SHARE ANALYSIS BY SINGLE-CELL ANALYSIS MAJOR PLAYERS
      • 3.11     COMPANY MATRIX ANALYSIS
    • 4     CELL ANALYSIS GLOBAL MARKET, BASED ON TECHNIQUES
      • 4.1     INTRODUCTION
        • 4.1.1     PCR (POLYMERASE CHAIN REACTION)
        • 4.1.2     SEQUENCING
        • 4.1.3     MICROFLUIDICS AND MICROARRAYS
        • 4.1.4     SPECTROMETRY
        • 4.1.5     MICROSCOPY
        • 4.1.6     CYTOMETRY
        • 4.1.7     HIGH CONTENT SCREENING
        • 4.1.8     ELECTROPHORESIS
        • 4.1.9     OTHERS
    • 5     CELL ANALYSIS GLOBAL MARKET, BASED ON PRODUCTS
      • 5.1     INTRODUCTION
      • 5.2     CONSUMABLES
        • 5.2.1     ASSAY KITS
        • 5.2.2     REAGENTS
        • 5.2.3     MICROPLATES
        • 5.2.4     OTHERS
      • 5.3     INSTRUMENTS
        • 5.3.1     CELL COUNTERS
        • 5.3.2     CELL MICROARRAYS AND MICROFLUIDICS
        • 5.3.3     LIQUID HANDLING SYSTEMS
        • 5.3.4     CYTOMETERS
        • 5.3.5     HIGH CONTENT SCREENING SYSTEMS
        • 5.3.6     MICROPLATE READERS
        • 5.3.7     PCR INSTRUMENTS
        • 5.3.8     SEQUENCING INSTRUMENTS
        • 5.3.9     SPECTROMETERS
        • 5.3.10     MICROSCOPES
        • 5.3.11     OTHER INSTRUMENTS
      • 5.4     SOFTWARE AND SERVICES
    • 6     CELL ANALYSIS GLOBAL MARKET, BASED ON APPLICATION
      • 6.1     INTRODUCTION
      • 6.2     CELL ANALYSIS GLOBAL MARKET, BASED ON THE PROCESS OF
        • 6.2.1     CELLULAR PROCESSES
        • 6.2.2     SIGNAL TRANSDUCTION PATHWAY
        • 6.2.3     CIRCULATING TUMOR CELLS
        • 6.2.4     SINGLE-CELL ANALYSIS
        • 6.2.5     EPIGENETIC TARGET ANALYSIS
        • 6.2.6     SUBPOPULATION CHARACTERIZATION
        • 6.2.7     DRUG AND CANDIDATE SCREENING
      • 6.3     CELL ANALYSIS GLOBAL MARKET, BASED ON THE FIELD OF APPLICATION
        • 6.3.1     FORENSICS
        • 6.3.2     THERAPEUTICS
        • 6.3.3     GENOMIC ANALYSIS
        • 6.3.4     STEM CELL ANALYSIS
        • 6.3.5     BIOMARKER RESEARCH
        • 6.3.6     CELL IMAGING
          • 6.3.6.1     LIVE-CELL IMAGING
        • 6.3.7     DIAGNOSTICS
      • 6.4     CELL ANALYSIS GLOBAL MARKET, BASED ON THERAPEUTIC AREA OF APPLICATIONS
        • 6.4.1     CANCER
        • 6.4.2     GENETIC TESTING
        • 6.4.3     INFECTIOUS DISEASES
        • 6.4.4     IMMUNOLOGY
        • 6.4.5     OTHERS
    • 7     CELL ANALYSIS GLOBAL MARKET, BASED ON END-USERS
      • 7.1     INTRODUCTION
      • 7.2     HOSPITALS AND DIAGNOSTIC LABORATORIES
      • 7.3     ACADEMIC & RESEARCH LABORATORIES
      • 7.4     PHARMACEUTICALS AND BIOTECH COMPANIES
      • 7.5     CONTRACT RESEARCH ORGANISATIONS
      • 7.6     CELL BANKS
      • 7.7     OTHERS
    • 8     REGIONAL MARKET ANALYSIS
      • 8.1     INTRODUCTION
      • 8.2     NORTH AMERICA
        • 8.2.1     UNITED STATES (U.S.)
        • 8.2.2     REST OF NORTH AMERICA
      • 8.3     EUROPE
        • 8.3.1     GERMANY
        • 8.3.2     FRANCE
        • 8.3.3     U.K.
        • 8.3.4     REST OF EUROPE
      • 8.4     ASIA PACIFIC
        • 8.4.1     JAPAN
        • 8.4.2     CHINA
        • 8.4.3     INDIA
        • 8.4.4     REST OF APAC
      • 8.5     REST OF THE WORLD
        • 8.5.1     BRAZIL
        • 8.5.2     REST OF LATIN AMERICA
        • 8.5.3     MIDDLE EAST AND AFRICA
    • 9     COMPETITIVE LANDSCAPE
      • 9.1     INTRODUCTION
      • 9.2     NEW PRODUCT LAUNCH
      • 9.3     APPROVAL
      • 9.4     AGREEMENTS, PARTNERSHIPS AND COLLABORATIONS
      • 9.5     ACQUISITIONS
      • 9.6     EXPANSION
    • 10     MAJOR PLAYER PROFILES
      • 10.1     10X GENOMICS, INC.
        • 10.1.1     OVERVIEW
        • 10.1.2     FINANCIALS
        • 10.1.3     PRODUCT PORTFOLIO
        • 10.1.4     KEY DEVELOPMENTS
        • 10.1.5     BUSINESS STRATEGY
        • 10.1.6     SWOT ANALYSIS
      • 10.2     ABBOTT LABORATORIES, INC
        • 10.2.1     OVERVIEW
        • 10.2.2     FINANCIALS
        • 10.2.3     PRODUCT PORTFOLIO
        • 10.2.4     KEY DEVELOPMENTS
        • 10.2.5     BUSINESS STRATEGY
        • 10.2.6     SWOT ANALYSIS
      • 10.3     AGILENT TECHNOLOGIES, INC.
        • 10.3.1     OVERVIEW
        • 10.3.2     FINANCIALS
        • 10.3.3     PRODUCT PORTFOLIO
        • 10.3.4     KEY DEVELOPMENTS
        • 10.3.5     BUSINESS STRATEGY
        • 10.3.6     SWOT ANALYSIS
      • 10.4     BECTON DICKINSON AND COMPANY
        • 10.4.1     OVERVIEW
        • 10.4.2     FINANCIALS
        • 10.4.3     PRODUCT PORTFOLIO
        • 10.4.4     KEY DEVELOPMENTS
        • 10.4.5     BUSINESS STRATEGY
        • 10.4.6     SWOT ANALYSIS
      • 10.5     BIO-RAD LABORATORIES, INC
        • 10.5.1     OVERVIEW
        • 10.5.2     FINANCIALS
        • 10.5.3     PRODUCT PORTFOLIO
        • 10.5.4     KEY DEVELOPMENTS
        • 10.5.5     BUSINESS STRATEGY
        • 10.5.6     SWOT ANALYSIS
      • 10.6     DANAHER CORPORATION
        • 10.6.1     OVERVIEW
        • 10.6.2     FINANCIALS
        • 10.6.3     PRODUCT PORTFOLIO
        • 10.6.4     KEY DEVELOPMENTS
        • 10.6.5     BUSINESS STRATEGY.
        • 10.6.6     SWOT ANALYSIS
      • 10.7     F.HOFFMANN-LA ROCHE LTD
        • 10.7.1     OVERVIEW
        • 10.7.2     FINANCIALS
        • 10.7.3     PRODUCT PORTFOLIO
        • 10.7.4     KEY DEVELOPMENTS
        • 10.7.5     BUSINESS STRATEGY
        • 10.7.6     SWOT ANALYSIS
      • 10.8     ILLUMINA, INC.
        • 10.8.1     OVERVIEW
        • 10.8.2     FINANCIALS
        • 10.8.3     PRODUCT PORTFOLIO
        • 10.8.4     KEY DEVELOPMENTS
        • 10.8.5     BUSINESS STRATEGY
        • 10.8.6     SWOT ANALYSIS
      • 10.9     MERCK KGAA
        • 10.9.1     OVERVIEW
        • 10.9.2     FINANCIALS
        • 10.9.3     PRODUCT PORTFOLIO
        • 10.9.4     KEY DEVELOPMENTS
        • 10.9.5     BUSINESS STRATEGY
        • 10.9.6     SWOT ANALYSIS
      • 10.10     PERKINELMER, INC.
        • 10.10.1     OVERVIEW
        • 10.10.2     FINANCIALS
        • 10.10.3     PRODUCT PORTFOLIO
        • 10.10.4     KEY DEVELOPMENTS
        • 10.10.5     BUSINESS STRATEGY
        • 10.10.6     SWOT ANALYSIS
      • 10.11     QIAGEN N.V
        • 10.11.1     OVERVIEW
        • 10.11.2     FINANCIALS
        • 10.11.3     PRODUCT PORTFOLIO
        • 10.11.4     KEY DEVELOPMENTS
        • 10.11.5     BUSINESS STRATEGY
        • 10.11.6     SWOT ANALYSIS
      • 10.12     THERMO FISHER SCIENTIFIC, INC.
        • 10.12.1     OVERVIEW
        • 10.12.2     FINANCIALS
        • 10.12.3     PRODUCT PORTFOLIO
        • 10.12.4     KEY DEVELOPMENTS
        • 10.12.5     BUSINESS STRATEGY
        • 10.12.6     SWOT ANALYSIS

        LIST OF TABLES

        • TABLE 1     CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 2     CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON TECHNIQUE, (2021-2029) ($MN)
        • TABLE 3     PCR IN CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 4     SEQUENCING IN CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 5     MICROFLUIDICS AND MICROARRAY IN CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 6     SPECTROMETRY IN CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 7     MICROSCOPY IN CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 8     CYTOMETRY IN CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 9     HIGH CONTENT SCREENING CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 10     ELECTROPHORESIS CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 11     OTHERS CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 12     CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
        • TABLE 13     CELL ANALYSIS CONSUMABLES GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
        • TABLE 14     CELL ANALYSIS CONSUMABLES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 15     CELL ANALYSIS ASSAY KITS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 16     CELL ANALYSIS REAGENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 17     CELL ANALYSIS MICROPLATES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 18     OTHER CONSUMABLES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 19     CELL ANALYSIS INSTRUMENTS GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
        • TABLE 20     CELL ANALYSIS INSTRUMENTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 21     CELL COUNTERS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 22     CELL MICROARRAYS AND MICROFLUIDICS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 23     LIQUID HANDLING SYSTEMS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 24     CYTOMETERS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 25     HIGH CONTENT SCREENING GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 26     MICROPLATE READERS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 27     PCR INSTRUMENTS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 28     SEQUENCING INSTRUMENTS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 29     SPECTROMETERS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 30     MICROSCOPES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 31     OTHER INSTRUMENTS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 32     SOFTWARE AND SERVICES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 33     CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON PROCESS OF APPLICATION, (2021-2029) ($MN)
        • TABLE 34     CELLULAR PROCESSES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 35     SIGNAL TRANSDUCTION PATHWAY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 36     CIRCULATING TUMOR CELLS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 37     SINGLE-CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 38     EPIGENETIC TARGET ANALYSIS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 39     SUBPOPULATION CHARACTERIZATION GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 40     DRUG AND CANDIDATE SCREENING GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 41     CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON FIELD OF APPLICATION, (2021-2029) ($MN)
        • TABLE 42     FORENSICS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 43     THERAPEUTICS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 44     GENOMIC ANALYSIS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 45     STEM CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 46     BIOMARKER RESEARCH GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 47     CELL IMAGING GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 48     LIVE CELL IMAGING GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 49     DIAGNOSTICS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 50     CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON THERAPEUTIC AREA OF APPLICATION, (2021-2029) ($MN)
        • TABLE 51     CANCER RESEARCH GLOBAL MARKET REVENUE BASED ON REGION, (2021-2029) ($MN)
        • TABLE 52     GENETIC TESTING GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 53     INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 54     IMMUNOLOGY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 55     OTHER THERAPEUTICS GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
        • TABLE 56     CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
        • TABLE 57     HOSPITALS AND DIAGNOSTIC LABORATORIES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 58     ACADEMIC & RESEARCH LABORATORIES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 59     PHARMA & BIOTECH COMPANIES GLOBAL MARKET REVENUE BASED ON REGION, (2021-2029) ($MN)
        • TABLE 60     CRO’S GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 61     CELL BANKS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 62     OTHER END-USERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 63     CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
        • TABLE 64     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BASED ON TECHNIQUE, (2021-2029) ($MN)
        • TABLE 65     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS, (2021-2029) ($MN)
        • TABLE 66     NORTH AMERICA CELL ANALYSIS CONSUMABLES MARKET REVENUE, BASED ON PRODCUT TYPE, (2021-2029) ($MN)
        • TABLE 67     NORTH AMERICA CELL ANALYSIS INSTRUMENTS MARKET REVENUE, BASED ON PRODCUT TYPE, (2021-2029) ($MN)
        • TABLE 68     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BASED ON PROCESS OF APPLICATION, (2021-2029) ($MN)
        • TABLE 69     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BASED ON FIELD OF APPLICATION, (2021-2029) ($MN)
        • TABLE 70     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BASED ON THERAPEUTIC AREA OF APPLICATION, (2021-2029) ($MN)
        • TABLE 71     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BASED ON END-USER, (2021-2029) ($MN)
        • TABLE 72     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
        • TABLE 73     EUROPE CELL ANALYSIS MARKET REVENUE, BASED ON TECHNIQUE, (2021-2029) ($MN)
        • TABLE 74     EUROPE CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS, (2021-2029) ($MN)
        • TABLE 75     EUROPE CELL ANALYSIS CONSUMABLES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
        • TABLE 76     EUROPE CELL ANALYSIS INSTRUMENTS MARKET REVENUE, BASED ON PRODUT TYPE, (2021-2029) ($MN)
        • TABLE 77     EUROPE CELL ANALYSIS MARKET REVENUE, BASED ON PROCESS OF APPLICATION, (2021-2029) ($MN)
        • TABLE 78     EUROPE CELL ANALYSIS MARKET REVENUE, BASED ON FIELD OF APPLICATION, (2021-2029) ($MN)
        • TABLE 79     EUROPE CELL ANALYSIS MARKET REVENUE, BASED ON THERAPEUTIC AREA OF APPLICATION, (2021-2029) ($MN)
        • TABLE 80     EUROPE CELL ANALYSIS MARKET REVENUE, BASED ON END-USER, (2021-2029) ($MN)
        • TABLE 81     EUROPE CELL ANALYSIS MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
        • TABLE 82     APAC CELL ANALYSIS MARKET REVENUE, BASD ON TECHNIQUE,(2021-2029) ($MN)
        • TABLE 83     APAC CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS, (2021-2029) ($MN)
        • TABLE 84     APAC CELL ANALYSIS CONSUMABLES MARKET REVENUE, BASED ON PRODUT TYPE, (2021-2029) ($MN)
        • TABLE 85     APAC CELL ANALYSIS INSTRUMENTS MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
        • TABLE 86     APAC CELL ANALYSIS MARKET REVENUE, BASED ON PROCESS OF APPLICATION, (2021-2029) ($MN)
        • TABLE 87     APAC CELL ANALYSIS MARKET REVENUE, BASED ON FIELD OF APPLICATION, (2021-2029) ($MN)
        • TABLE 88     APAC CELL ANALYSIS MARKET REVENUE, BASED ON THERAPEUTIC AREA OF APPLICATION, (2021-2029) ($MN)
        • TABLE 89     APAC CELL ANALYSIS MARKET REVENUE, BASED ON END-USER, (2021-2029) ($MN)
        • TABLE 90     APAC CELL ANALYSIS MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
        • TABLE 91     ROW CELL ANALYSIS MARKET REVENUE, BASED ON TECHNIQUE, (2021-2029) ($MN)
        • TABLE 92     ROW CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS, (2021-2029) ($MN)
        • TABLE 93     ROW CELL ANALYSIS CONSUMABLES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
        • TABLE 94     ROW CELL ANALYSIS INSTRUMENTS MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
        • TABLE 95     ROW CELL ANALYSIS MARKET REVENUE, BASED ON PROCESS OF APPLICATION, (2021-2029) ($MN)
        • TABLE 96     ROW CELL ANALYSIS MARKET REVENUE, BASED ON FIELD OF APPLICATION, (2021-2029)($MN)
        • TABLE 97     ROW CELL ANALYSIS MARKET REVENUE, BASED ON THERAPEUTIC AREA OF APPLICATION, (2021-2029) ($MN)
        • TABLE 98     ROW CELL ANALYSIS MARKET REVENUE, BY END-USER, (2021-2029) ($MN)
        • TABLE 99     ROW CELL ANALYSIS MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
        • TABLE 100     NEW PRODUCT LAUNCH (2020-2022)*
        • TABLE 101     APPROVALS (2020-2022)*
        • TABLE 102     AGREEMENTS, PARTNERSHIPS AND COLLABORATIONS (2020-2022)*
        • TABLE 103     ACQUISITIONS (2020-2022)*
        • TABLE 104     OTHERS (2019-2020)
        • TABLE 105     10X GENOMICS, INC. : TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q1)($MN)
        • TABLE 106     10X GENOMICS, INC. : TOTAL REVENUE BY SEGMENT, (2020-2022)(Q2) ($MN)
        • TABLE 107     10X GENOMICS, INC. : TOTAL REVENUE, BY REGION, (2020-2022)(Q1) ($MN)
        • TABLE 108     ABBOTT LABORATORIES, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020 -2022) (Q2) ($MN)
        • TABLE 109     ABBOTT LABORATORIES, INC.: TOTAL REVENUE BY SEGMENT, (2020-2022)(Q2) ($MN)
        • TABLE 110     ABBOTT LABORATORIES, INC.: TOTAL REVENUE BY SUB-SEGMENT, (2020-2022)(Q2) ($MN)
        • TABLE 111     ABBOTT LABORATORIES, INC.: TOTAL REVENUE, BY REGION, (2020-2022) (Q2)($MN)
        • TABLE 112     AGILENT TECHNOLOGIES, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2) ($MN)
        • TABLE 113     AGILENT TECHNOLOGIES, INC.: TOTAL REVENUE BY SEGMENT, (2020-2022) (Q2) ($MN)
        • TABLE 114     AGILENT TECHNOLOGIES, INC.: TOTAL REVENUE, BY REGION, (2020-2022) (Q2) ($MN)
        • TABLE 115     BECTON DICKINSON AND COMPANY: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q2)($MN)
        • TABLE 116     BECTON DICKINSON AND COMPANY: TOTAL REVENUE BY SEGMENT, (2020-2022) (Q2) ($MN)
        • TABLE 117     BECTON DICKINSON AND COMPANY: LIFE SCIENCES REVENUE BY SUB - SEGMENT, (2020-2022) (Q2) ($MN)
        • TABLE 118     BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY REGION, (2020-2022) (Q2) ($MN)
        • TABLE 119     BIO-RAD LABORATORIES, INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q1) ($MN)
        • TABLE 120     BIO-RAD LABORATORIES: TOTAL REVENUE BY SEGMENT, (2020-2022) (Q1) ($MN)
        • TABLE 121     BIO-RAD LABORATORIES: TOTAL REVENUE, BY REGION, (2020-2022) (Q1) ($MN)
        • TABLE 122     DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES (2020-2022) (Q2) ($MN)
        • TABLE 123     DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENT, (2020-2022)(Q2) ($MN)
        • TABLE 124     DANAHER CORPORATION: TOTAL REVENUE, BY REGION, (2020-2022) (Q2) ($MN)
        • TABLE 125     F.HOFFMANN-LA RACHE: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2) ($MN)
        • TABLE 126     F.HOFFMANN-LA ROCHE: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q2) ($MN)
        • TABLE 127     F.HOFFMANN-LA ROCHE: DIAGNOSTICS REVENUE, BY SEGMENTS (2020-2022) (Q2) ($MN)
        • TABLE 128     F.HOFFMAN LA ROCHE: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q2) ($MN)
        • TABLE 129     ILLUMINA, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2021) (Q1) ($MN)
        • TABLE 130     ILLUMINA, INC.: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q1) ($MN)
        • TABLE 131     ILLUMINA, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022)(Q1) ($MN)
        • TABLE 132     MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q1) ($MN)
        • TABLE 133     MERCK KGAA: TOTAL REVENUE, BY SEGMENT, (2020-2022) (Q1) ($MN)
        • TABLE 134     MERCK KGAA COMPANY: TOTAL REVENUE, BY LIFE-SCIENCE SUB-SEGMENTS, (2020-2022) (Q1) ($MN)
        • TABLE 135     MERCK KGAA COMPANY: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q1) ($MN)
        • TABLE 136     PERKINELMER, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q1) ($MN)
        • TABLE 137     PERKINELMER, INC.: TOTAL REVENUE BY SEGMENT, (2020-2022) (Q1) ($MN)
        • TABLE 138     PERKINELMER, INC.: TOTAL REVENUE, BY REGION, (2020-2022) (Q2) ($MN)
        • TABLE 139     QIAGEN N.V.: TOTAL REVENUE AND R&D EXPENSES, (2020 -2022) (Q1) ($MN)
        • TABLE 140     QIAGEN N.V.: TOTAL REVENUE BY SEGMENT, (2020-2022)(Q1) ($MN)
        • TABLE 141     QIAGEN N.V.: TOTAL REVENUE, BY REGION, (2020-2022) (Q1)($MN)
        • TABLE 142     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q1) ($MN)
        • TABLE 143     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENT, (2020-2022) (Q1) ($MN)
        • TABLE 144     THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022)(Q1) ($MN)

        LIST OF FIGURES

        • FIGURE 1     CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON GEOGRAPHY (2021-2029)($MN)
        • FIGURE 2     RESEARCH METHODOLOGY: CELL ANALYSIS GLOBAL MARKET
        • FIGURE 3     CELL ANALYSIS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
        • FIGURE 4     CELL ANALYSIS GLOBAL MARKET: FORECASTING MODEL
        • FIGURE 5     CELL ANALYSIS GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
        • FIGURE 6     CELL ANALYSIS GLOBAL MARKET: MARKET SEGMENTATION
        • FIGURE 7     MARKET DYNAMICS
        • FIGURE 8     CELL ANALYSIS GLOBAL MARKET: PORTER’S ANALYSIS
        • FIGURE 9     CELL ANALYSIS GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, (2022) (%)
        • FIGURE 10     SINGLE-CELL ANALYSIS GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, (2022) (%)
        • FIGURE 11     CELL ANALYSIS GLOBAL MARKET SHARE, BASED ON TECHNIQUES (2022 VS 2029) (%)
        • FIGURE 12     ELECTROPHORESIS IN CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON REGION, (2022 VS 2029) (%)
        • FIGURE 13     CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON PRODUCTS AND CONSUMABLES SUB-SEGMENT, (2022) ($MN)
        • FIGURE 14     CELL ANALYSIS INSTRUMENTS GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)
        • FIGURE 15     CELL ANALYSIS GLOBAL MARKET SHARE, BASED ON PROCESS OF APPLICATION (2022 V/S 2029) (%)
        • FIGURE 16     CIRCULATING TUMOR CELLS GLOBAL MARKET REVENUE, BASED ON REGION, (2022 VS 2029) (%)
        • FIGURE 17     CELL ANALYSIS GLOBAL MARKET SHARE, BASED ON FIELD OF APPLICATION (2022 V/S 2029) (%)
        • FIGURE 18     GENOMIC ANALYSIS GLOBAL MARKET REVENUE, BASED ON REGION, (2022 VS 2029) (%)
        • FIGURE 19     CELL ANALYSIS GLOBAL MARKET SHARE, BASED ON THERAPEUTIC AREA OF APPLICATION (2022 V/S 2029) (%)
        • FIGURE 20     CELL ANALYSIS GLOBAL MARKET SHARE, BASED ON END-USERS (2022 V/S 2029) (%)
        • FIGURE 21     CELL ANALYSIS MARKET GLOBAL REVENUE, BASED ON REGION (2021-2029) ($MN)
        • FIGURE 22     CELL ANALYSIS GLOBAL MARKET REVENUE, BASED ON GEOGRAPHY (2022) ($ MN)
        • FIGURE 23     NORTH AMERICA CELL ANALYSIS MARKET SHARE, BASED ON TECHNIQUE (2022 V/S 2029) (%)
        • FIGURE 24     NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCT AND CONSUMABLES SUB - SEGMENT (2022) ($MN)
        • FIGURE 25     NORTH AMERICA CELL ANALYSIS INSTRUMENTS MARKET SHARE, BASED ON PRODCUT TYPE (2022 VS 2029) (%)
        • FIGURE 26     NORTH AMERICA CELL ANALYSIS MARKET SHARE, BASED ON PROCESS OF APPLICATION (2021 V/S 2029) (%)
        • FIGURE 27     NORTH AMERICA CELL ANALYSIS MARKET SHARE, BASED ON FIELD OF APPLICATION (2022 V/S 2029) (%)
        • FIGURE 28     NORTH AMERICA CELL ANALYSIS MARKET SHARE, BASED ON THERAPEUTIC AREA OF APPLICATION (2022 V/S 2029) (%)
        • FIGURE 29     NORTH AMERICA CELL ANALYSIS MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
        • FIGURE 30     NORTH AMERICA CELL ANALYSIS MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
        • FIGURE 31     U.S CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS, PROCESS OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 32     U.S. CELL ANALYSIS MARKET REVENUE, BASED ON FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 33     U.S. CELL ANALYSIS APPLICATION MARKET REVENUE, BASED ON END-USER (2022 V/S 2029) ($MN)
        • FIGURE 34     REST OF NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS, PROCESS OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 35     REST OF NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BASED ON FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 36     REST OF NORTH AMERICA CELL ANALYSIS MARKET REVENUE, BASED ON END-USER (2022 VS 2029) ($MN)
        • FIGURE 37     EUROPE CELL ANALYSIS MARKET SHARE, BASED ON TECHNIQUE (2022 VS 2029) (%)
        • FIGURE 38     EUROPE CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS AND CONSUMABLES SUB-SEGMENT (2022) ($MN)
        • FIGURE 39     EUROPE CELL ANALYSIS INSTRUMENTS MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) ($MN)
        • FIGURE 40     EUROPE CELL ANALYSIS MARKET SHARE, BASED ON PROCESS OF APPLICATION (2022 V/S 2029) (%)
        • FIGURE 41     EUROPE CELL ANALYSIS MARKET SHARE, BASED ON FIELD OF APPLICATION (2022 V/S 2029) (%)
        • FIGURE 42     EUROPE CELL ANALYSIS MARKET SHARE, BASED ON THERAPEUTIC AREA APPLICATION (2022 V/S 2029) (%)
        • FIGURE 43     EUROPE CELL ANALYSIS MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
        • FIGURE 44     EUROPE CELL ANALYSIS MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
        • FIGURE 45     GERMANY CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS, PROCESS OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 46     GERMANY CELL ANALYSIS MARKET REVENUE, BASED ON FIELD OF APPLICATION AND THERAPUTIC AREA OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 47     GERMANY CELL ANALYSIS MARKET REVENUE, BASED ON END-USER (2022 V/S 2029) ($MN)
        • FIGURE 48     FRANCE CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS, PROCESS OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 49     FRANCE CELL ANALYSIS MARKET REVENUE, BASED ON FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 50     FRANCE CELL ANALYSIS MARKET REVENUE, BASED ON END-USER (2022 V/S 2029) ($MN)
        • FIGURE 51     U.K. CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS, PROCESS OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 52     U.K. CELL ANALYSIS MARKET REVENUE, BASED ON FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 53     U.K. CELL ANALYSIS MARKET REVENUE, BASED ON END-USER (2022 V/S 2029) ($MN)
        • FIGURE 54     REST OF EUROPE CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS, PROCESS OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 55     REST OF EUROPE CELL ANALYSIS MARKET REVENUE, BASED ON FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 56     REST OF EUROPE CELL ANALYSIS MARKET REVENUE, BASED ON END-USER (2022 V/S 2029) ($MN)
        • FIGURE 57     APAC CELL ANALYSIS MARKET SHARE, BASED ON TECHNIQUE (2022) (%)
        • FIGURE 58     APAC CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS AND CONSUMABLES SUB-SEGMENT (2022) ($MN)
        • FIGURE 59     APAC CELL ANALYSIS MARKET SHARE, BASED ON INSTRUMENTS (2022 V/S 2029) (%)
        • FIGURE 60     APAC CELL ANALYSIS MARKET SHARE, BY PROCESS OF APPLICATION (2022 V/S 2029) (%)
        • FIGURE 61     APAC CELL ANALYSIS MARKET SHARE, BASED ON FIELD OF APPLICATION (2022 V/S 2029) (%)
        • FIGURE 62     APAC CELL ANALYSIS MARKET SHARE, BASED ON THERAPEUTIC AREA OF APPLICATION (2022 V/S 2029) (%)
        • FIGURE 63     APAC CELL ANALYSIS MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
        • FIGURE 64     APAC CELL ANALYSIS MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
        • FIGURE 65     JAPAN CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS, PROCESS OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 66     JAPAN CELL ANALYSIS MARKET REVENUE, BASED ON FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 67     JAPAN CELL ANALYSIS MARKET REVENUE, BASED ON END-USER (2022 V/S 2029) ($MN)
        • FIGURE 68     CHINA CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS, PROCESS OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 69     CHINA CELL ANALYSIS MARKET REVENUE, BASED ON FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 70     CHINA CELL ANALYSIS MARKET REVENUE, BASED ON END-USER (2022 V/S 2029) ($MN)
        • FIGURE 71     INDIA CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS, PROCESS OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 72     INDIA CELL ANALYSIS MARKET REVENUE, BASED ON FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 73     INDIA CELL ANALYSIS MARKET REVENUE, BASED ON END-USER (2022 VS 2029) ($MN)
        • FIGURE 74     REST OF APAC CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS, PROCESS OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 75     REST OF APAC CELL ANALYSIS MARKET REVENUE, BASED ON FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 76     REST OF APAC CELL ANALYSIS MARKET REVENUE, BASED ON END-USER (2022 V/S 2029) ($MN)
        • FIGURE 77     REST OF THE WORLD CELL ANALYSIS MARKET SHARE, BASED ON TECHNIQUE (2022) (%)
        • FIGURE 78     REST OF THE WORLD CELL ANALYSIS MARKET SHARE, BASED ON PRODUCTS AND CONSUMABLES SUB-SEGMENT (2022) ($MN)
        • FIGURE 79     REST OF THE WORLD CELL ANALYSIS MARKET SHARE, BASED ON INSTRUMENTS (2022 V/S 2029) (%)
        • FIGURE 80     REST OF THE WORLD CELL ANALYSIS MARKET SHARE, BASED ON PROCESS OF APPLICATION (2022 V/S 2029) (%)
        • FIGURE 81     REST OF THE WORLD CELL ANALYSIS MARKET SHARE, BASED ON FIELD OF APPLICATION (2022 V/S 2029) (%)
        • FIGURE 82     REST OF THE WORLD CELL ANALYSIS MARKET SHARE, BASED ON THERAPEUTIC AREA APPLICATION (2022 V/S 2029) (%)
        • FIGURE 83     REST OF THE WORLD CELL ANALYSIS MARKET SHARE, BASED ON END-USER (2022 V/S 2029) (%)
        • FIGURE 84     REST OF THE WORLD CELL ANALYSIS MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
        • FIGURE 85     BRAZIL CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS, PROCESS OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 86     BRAZIL CELL ANALYSIS MARKET REVENUE, BASED ON FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 87     BRAZIL CELL ANALYSIS MARKET REVENUE, BASED ON END-USER (2022 V/S 2029) ($MN)
        • FIGURE 88     REST OF LATAM CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS, PROCESS OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 89     REST OF LATAM CELL ANALYSIS MARKET REVENUE, BASED ON FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 90     REST OF LATAM CELL ANALYSIS MARKET REVENUE, BASED ON END-USER (2022 V/S 2029) ($MN)
        • FIGURE 91     MIDDLE EAST AND AFRICA CELL ANALYSIS MARKET REVENUE, BASED ON PRODUCTS, PROCESS OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 92     MIDDLE EAST AND AFRICA CELL ANALYSIS MARKET REVENUE, BASED ON FIELD OF APPLICATION, THERAPEUTIC AREA OF APPLICATION (2022 V/S 2029) ($MN)
        • FIGURE 93     MIDDLE EAST AND AFRICA CELL ANALYSIS MARKET REVENUE, BASED ON END-USER (2022 V/S 2029) ($MN)
        • FIGURE 94     KEY GROWTH STRATEGIES (2020-2022*)
        • FIGURE 95     SWOT: 10X GENOMICS
        • FIGURE 96     SWOT: ABBOTT LABORATORIES, INC.
        • FIGURE 97     SWOT: AGILENT TECHNOLOGIES
        • FIGURE 98     SWOT: BECTON DICKINSON AND COMPANY
        • FIGURE 99     SWOT: BIO-RAD LABORATORIES INC.
        • FIGURE 100     SWOT: DANAHER CORPORATION
        • FIGURE 101     SWOT: F. HOFFMANN-LA ROCHE LTD.
        • FIGURE 102     SWOT: ILLUMINA INC.
        • FIGURE 103     SWOT: MERCK KGAA
        • FIGURE 104     SWOT: PERKINELMER, INC
        • FIGURE 105     SWOT: QIAGEN N V
        • FIGURE 106     SWOT: THERMO FISHER SCIENTIFIC

        LIST OF COMPANIES MENTIONED IN REPORT

        • 1     10X Genomics
        • 2     1CellBio
        • 3     Abbexa Ltd
        • 4     Abbott Laboratories, Inc.
        • 5     Abcam Plc.
        • 6     Abnova Corporation
        • 7     ABP Biosciences LLC
        • 8     Adaptive Biotechnologies Corp.
        • 9     Agilent Technologies Inc. (U.S.)
        • 10     Aigenpulse
        • 11     Akadeum Life Sciences
        • 12     Akoya Biosciences, Inc.
        • 13     Alit Lifesciences Co., Ltd
        • 14     Altona Diagnostics GmbH
        • 15     Analytik Jena AG (CyBio AG)
        • 16     ArrayGen Technologies Pvt Ltd (India)
        • 17     Art Robbins Instruments LLC (U.S.)
        • 18     Aviva Bioscience (U.S.)
        • 19     Axion Biosystems (CytoSMART Technologies B.V.) (U.S.)
        • 20     Azenta Life Sciences (Brooks life sciences)
        • 21     Becton Dickinson and Company
        • 22     BennuBio Inc.
        • 23     Berry Genomics Co., Ltd
        • 24     BGI Group
        • 25     Bico (Cellenion)
        • 26     Bio View Ltd.
        • 27     BioAgilytix Labs, LLC (Cambridge Biomedical Inc.)
        • 28     Biochrom Ltd.
        • 29     Biofluidica
        • 30     BioinGentech
        • 31     Bioneer Corporation
        • 32     Bio-Rad Laboratories Inc.
        • 33     Bioron GmbH
        • 34     BioSkryb, Inc.
        • 35     Bio-Techne Corporation
        • 36     Biotium
        • 37     bitBiome, Inc.
        • 38     Blue-Ray Biotech
        • 39     Brand GMBH
        • 40     Bruker Corporation
        • 41     Carl Zeiss AG
        • 42     CeGaT GmbH
        • 43     Cell Biolabs, Inc.
        • 44     Cell Microsystems
        • 45     Cell Signaling Technology, Inc.
        • 46     CellChorus
        • 47     CellTool
        • 48     Celsius Therapeutics
        • 49     Celtic Molecular Diagnostics
        • 50     Cherry Biotech
        • 51     Cleaver Scientific
        • 52     Corning Inc.
        • 53     Cytek Biosciences
        • 54     CytoTronics
        • 55     Da An Gene Co., Ltd.,
        • 56     DeepCell, Inc.
        • 57     DiaSorin (Luminex Corporation)
        • 58     DLAB Scientific Co., Ltd.,
        • 59     Dolomite Bio
        • 60     Eikon Therapeutics
        • 61     Element Biosciences
        • 62     Enzo life sciences Inc.
        • 63     Epigenomics AG
        • 64     Eppendorf
        • 65     Etaluma Inc
        • 66     Eurofins Scientific
        • 67     Fluent BioSciences
        • 68     Fluidigm Corporation
        • 69     Fluxion Biosciences
        • 70     GC biotech B.V.
        • 71     Genomatix AG
        • 72     GenXPro GmbH
        • 73     Hamilton Company
        • 74     Hausser Scientific
        • 75     Helena Laboratories Corporation
        • 76     Herolab GmbH
        • 77     Hettich Lab Technology
        • 78     HighQu GmbH
        • 79     Horiba, Ltd
        • 80     Illumina Inc.
        • 81     Immunai
        • 82     IncellDx
        • 83     Inscopix
        • 84     Insightful Science
        • 85     IsoPlexis
        • 86     Jasco Analytical Instruments
        • 87     JEOL Ltd
        • 88     Keyence Corporation
        • 89     Kinetic River Corp.
        • 90     Known Medicine
        • 91     Kromatid
        • 92     Kyratec
        • 93     LABGENE Scientific SA
        • 94     Levitas Bio
        • 95     LGC Ltd (Biosearch Technologies)
        • 96     Lucid Scientific
        • 97     Lonza Group
        • 98     Lunaphore Technologies
        • 99     LungLife AI, Inc
        • 100     LW Scientific
        • 101     Macrogen Inc
        • 102     Meiji Techno Co., Ltd
        • 103     Menarini Silicon Biosystems
        • 104     Merck KGaA
        • 105     METAFORA biosystems
        • 106     Micro-Shot Technology Ltd.
        • 107     Miltenyil Biotec GmbH
        • 108     Minos Biosciences
        • 109     Mission Bio, Inc.
        • 110     Myllia Biotechnology (Aelian Biotechnology)
        • 111     Namocell Inc.
        • 112     Nanolive SA
        • 113     NanoString Technologies, Inc.
        • 114     Nikon Corporation
        • 115     Novogene Co. Ltd
        • 116     Nucleai
        • 117     Oxford Nanopore Technologies, Ltd.
        • 118     Pacific Biosciences
        • 119     Paradigm4
        • 120     Parse Biosciences
        • 121     PerkinElmer
        • 122     Picoquant GmbH
        • 123     Plexium
        • 124     Polaris Biology
        • 125     Promega Corporation
        • 126     Promocell
        • 127     Qiagen N.V
        • 128     Rebus Biosystems
        • 129     Renishaw plc
        • 130     Roche Diagnostics
        • 131     Rosalind, Inc.
        • 132     S2 Genomics, Inc.
        • 133     Sartorius AG
        • 134     Scailyte AG
        • 135     Scipio bioscience S.A.S
        • 136     Scopio Labs
        • 137     seqWell
        • 138     Single Cell Discoveries
        • 139     Singleron Biotechnologies. Inc
        • 140     Singular Genomics Systems, Inc
        • 141     Sony Biotechnology
        • 142     Sphere Fluidics
        • 143     StemCell Technologies
        • 144     Stilla Technologies
        • 145     Sysmex Coperation
        • 146     Olympus Corporation
        • 147     Optika Srl
        • 148     Takara Bio
        • 149     ThinkCyte
        • 150     Tomocube Inc.
        • 151     Tracxn Technologies Limited (Capp Aps)
        • 152     Visitron Systems GmbH
        • 153     Vizgen, Inc.
        • 154     Yokogawa Electric Corporation
        • 155     Zymo Research